Table 2. Association of FGF-23 with baseline cognitive function in the health ABC study.
| FGF-23 | N | N with outcome | Model 1 | Model 2 | Model 3 |
|---|---|---|---|---|---|
| 3MSE score | β (95% CI) | β (95% CI) | β (95% CI) | ||
| Continuous (per 2-fold higher) | 2738 | - | -0.20 (-0.63, 0.24) | -0.10 (-0.49, 0.28) | -0.13 (-0.52, 0.27) |
| Quartiles | |||||
| < 36 | 683 | - | 0 (ref) | 0 (ref) | 0 (ref) |
| 36–46 | 685 | - | 0.76 (-0.08, 1.60) | 0.30 (-0.40, 0.99) | 0.29 (-0.41, 0.98) |
| 47–60 | 686 | - | 0.43 (-0.40, 1.27) | 0.27 (-0.43, 0.97) | 0.26 (-0.44, 0.97) |
| > 60 | 684 | - | -0.12 (-0.96, 0.72) | 0.01 (-0.72, 0.73) | -0.02 (-0.76, 0.73) |
| 3MSE < 80 at baseline | OR (95% CI) | OR (95% CI) | OR (95% CI) | ||
| Continuous (per 2-fold higher) | 2738 | 278 | 1.09 (0.91, 1.31) | 1.05 (0.86, 1.29) | 1.10 (0.89, 1.37) |
| Quartiles | |||||
| < 36 | 683 | 79 (12%) | 1.00 (ref) | 1.00 (ref) | 1.00 (ref) |
| 36–46 | 685 | 61 (9%) | 0.71 (0.49, 1.01) | 0.78 (0.52, 1.16) | 0.79 (0.53, 1.18) |
| 47–60 | 686 | 62 (9%) | 0.77 (0.54, 1.09) | 0.80 (0.54, 1.18) | 0.82 (0.55, 1.21) |
| > 60 | 684 | 76 (11%) | 0.93 (0.66, 1.30) | 0.84 (0.56, 1.24) | 0.88 (0.58, 1.33) |
| DSST score | β (95% CI) | β (95% CI) | β (95% CI) | ||
| Continuous (per 2-fold higher) | 2738 | - | 0.04 (-0.77, 0.86) | 0.21 (-0.45, 0.87) | 0.24 (-0.45, 0.92) |
| FGF-23 Quartiles | |||||
| < 36 | 683 | - | 0 (ref) | 0 (ref) | 0 (ref) |
| 36–46 | 685 | - | 0.58 (-0.98, 2.13) | -0.32 (-1.52, 0.89) | -0.33 (-1.54, 0.88) |
| 47–60 | 686 | - | 0.28 (-1.27, 1.84) | 0.06 (-1.15, 1.27) | 0.04 (-1.18, 1.27) |
| > 60 | 684 | - | 0.17 (-1.43, 1.70) | 0.48 (-0.76, 1.75) | 0.56 (-0.73, 1.85) |
Model 1 = unadjusted analysis.
Model 2 = adjusted for age, sex, race, study site, and education, diabetes, cardiovascular disease, hypertension, eGFR and ACR.
Model 3 = M2 + calcium, phosphorus, PTH, 25(OH) Vitamin D and klotho.